Literature DB >> 18482046

Mechanisms of preventive effect of nicorandil on ischaemia-induced ventricular tachyarrhythmia in isolated arterially perfused canine left ventricular wedges.

Masamichi Hirose1, Natsuko Tsujino, Tsutomu Nakada, Shiharu Yano, Hiroshi Imamura, Mitsuhiko Yamada.   

Abstract

Whether nicorandil is effective at preventing ventricular tachyarrhythmia (VT) during acute myocardial ischaemia is still controversial. We examined effects of nicorandil on the induction of VT during acute myocardial ischaemia. Optical action potentials were recorded from the entire transmural wall of arterially perfused canine left ventricular wedges. Ischaemia was produced by arterial occlusion for 20 min. During endocardial pacing, nicorandil shortened mean action potential duration (APD) in the transmural wall before ischaemia and further shortened it during ischaemia without increasing dispersion of APD. HMR1098, a selective blocker of sarcolemmal ATP-sensitive K(+) channels, inhibited the shortening of APD by nicorandil before and during ischaemia. Ischaemia decreased transmural conduction velocity (CV). Nicorandil partially restored CV to a similar extent in the absence and presence of HMR1098. In contrast, HMR1098 did not suppress the ischaemic conduction slowing in the absence of nicorandil. Nicorandil suppressed the increased dispersion of local CV during ischaemia. Isochrone maps on the initiation of VT showed that reentry in the transmural surface resulted from the excitation of the epicardial region of transmural surface. Nicorandil significantly increased the size of non-excited area in the epicardial region of the transmural wall, thereby significantly reducing the incidence of VT induced during ischaemia. HMR1098 inhibited this effect of nicorandil. These results suggest that nicorandil prevents VT during acute global ischaemia primarily by augmenting the inactivation of epicardial muscle through the activation of sarcolemmal K(ATP) channels.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18482046     DOI: 10.1111/j.1742-7843.2008.00242.x

Source DB:  PubMed          Journal:  Basic Clin Pharmacol Toxicol        ISSN: 1742-7835            Impact factor:   4.080


  6 in total

Review 1.  KATP Channels in the Cardiovascular System.

Authors:  Monique N Foster; William A Coetzee
Journal:  Physiol Rev       Date:  2016-01       Impact factor: 37.312

2.  Comparative effects of calcium and potassium channel modulators on ischemia/reperfusion injury in the isolated rat heart.

Authors:  Nina Simonovic; Vladimir Jakovljevic; Jovana Jeremic; Zarko Finderle; Ivan Srejovic; Tamara Nikolic Turnic; Isidora Milosavljevic; Vladimir Zivkovic
Journal:  Mol Cell Biochem       Date:  2018-06-19       Impact factor: 3.396

Review 3.  Use of nicorandil in cardiovascular disease and its optimization.

Authors:  Shigeo Horinaka
Journal:  Drugs       Date:  2011-06-18       Impact factor: 9.546

4.  Nicorandil normalizes prolonged repolarisation in the first transgenic rabbit model with Long-QT syndrome 1 both in vitro and in vivo.

Authors:  Jürgen Biermann; Kezhong Wu; Katja E Odening; Stefan Asbach; Gideon Koren; Xuwen Peng; Manfred Zehender; Christoph Bode; Michael Brunner
Journal:  Eur J Pharmacol       Date:  2010-10-17       Impact factor: 4.432

5.  Clinical outcomes of nicorandil administration in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a systematic review and meta-analysis of randomized controlled trials.

Authors:  Ning Geng; Li Ren; Lisheng Xu; Deling Zou; Wenyue Pang
Journal:  BMC Cardiovasc Disord       Date:  2021-10-10       Impact factor: 2.298

6.  Nicorandil prevents Gαq-induced progressive heart failure and ventricular arrhythmias in transgenic mice.

Authors:  Masamichi Hirose; Yasuchika Takeishi; Tsutomu Nakada; Hisashi Shimojo; Toshihide Kashihara; Ayako Nishio; Satoshi Suzuki; Ulrike Mende; Kiyoshi Matsumoto; Naoko Matsushita; Eiichi Taira; Fumika Sato; Mitsuhiko Yamada
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.